Emergent BioSolutions (EBS) Misses Q3 EPS by 3c, FY Revenue Guidance Beats
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.46 +3.86%
Revenue Growth %: -45.6%
Financial Fact:
Net income (loss) attributable to Emergent BioSolutions Inc.: 21.34M
Today's EPS Names:
RCBC, GASS, YSG, More
Revenue Growth %: -45.6%
Financial Fact:
Net income (loss) attributable to Emergent BioSolutions Inc.: 21.34M
Today's EPS Names:
RCBC, GASS, YSG, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of $0.55, $0.03 worse than the analyst estimate of $0.58. Revenue for the quarter came in at $173.7 million versus the consensus estimate of $184.1 million.
GUIDANCE:
Emergent BioSolutions sees FY2018 EPS of $770.00-$800.00, versus the consensus of $741.00.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Methode Electronics (MEI) Tops Q1 EPS by 2c; offers guidance
- Five Below raises full-year outlook after strong second-quarter sales growth
- Snowflake soars 20% on earnings beat and raised guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
